Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial

Autor: Blay, Jean-Yves *, *, Devin, Quentin *, Duffaud, Florence, Toulmonde, Maud, Firmin, Nelly, Collard, Olivier, Bompas, Emmanuelle, Verret, Benjamin, Ray-Coquard, Isabelle, Salas, Sebastien, Henon, Clemence, Honoré, Charles, Brahmi, Mehdi, Dufresne, Armelle, Pracht, Marc, Hervieu, Alice, Penel, Nicolas, Bertucci, Francois, Rios, Maria, Saada-Bouzid, Esma, Soibinet, Pauline, Perol, David, Chabaud, Sylvie, Italiano, Antoine, Cesne, Axel Le
Zdroj: In The Lancet Oncology September 2024 25(9):1163-1175
Databáze: ScienceDirect